The SF3b complex in cancer: structural basis, molecular mechanisms, and therapeutic opportunities.
New drugs targeting SF3B1 mutations show promise in lab studies of blood cancers where this mutation drives disease.
SF3B1 mutations, the most common spliceosome mutations in MDS (~25% frequency) and CLL, drive aberrant splicing of tumor suppressors and oncogenes; emerging small-molecule SF3b inhibitors show synthetic lethality in SF3B1-mutant hematologic cancers. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Narrative review
- Category
- Other
- Maturity
- Exploratory
- Journal
- Blood advances
Why it surfaced
Blood Advances (ASH flagship) review on SF3B1—the most actionable splicing mutation in hematologic malignancies. SF3B1 mutations define a distinct MDS subtype (MDS-SF3B1) with ring sideroblasts and are a diagnostic and therapeutic target; timely for precision hematology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.